Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Inman

Showing results (521-530 of 541) with videos related to

Pageof 55
Sort By:
JCI Insight|July 12, 2016
Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseasesGang Liu, Marion A Cooley, Andrew G Jarnicki, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 27, 2014
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concernsAtul Deodhar, John D Reveille, Filip van den Bosch, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Journal of Natural Products|December 2, 2011
Natural product libraries to accelerate the high-throughput discovery of therapeutic leadsTyler A Johnson, Johann Sohn, Wayne D Inman, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclatureDésirée van der Heijde, Anna Molto, Sofia Ramiro, et al.
Arthritis and Rheumatism|December 1, 1996
Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative StudyD O Clegg, D J Reda, M H Weisman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 16, 2023
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory DiseasesMichelle W Cheung, Roya M Dayam, Janna R Shapiro, et al.
Annals of the Rheumatic Diseases|May 5, 2011
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisJ Braun, R van den Berg, X Baraliakos, et al.
Arthritis Care & Research|September 25, 2015
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisMichael M Ward, Atul Deodhar, Elie A Akl, et al.
Pageof 55

Showing results (521-530 of 541) with videos related to

Sort By:
Pageof 55
JCI Insight|July 12, 2016
Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseasesGang Liu, Marion A Cooley, Andrew G Jarnicki, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 27, 2014
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concernsAtul Deodhar, John D Reveille, Filip van den Bosch, et al.
The Journal of Rheumatology|August 13, 2009
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteriaWalter P Maksymowych, Robert Landewé, Paul-Peter Tak, et al.
The Journal of Rheumatology|August 13, 2009
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study designWalter P Maksymowych, Oliver Fitzgerald, George A Wells, et al.
Journal of Natural Products|December 2, 2011
Natural product libraries to accelerate the high-throughput discovery of therapeutic leadsTyler A Johnson, Johann Sohn, Wayne D Inman, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclatureDésirée van der Heijde, Anna Molto, Sofia Ramiro, et al.
Arthritis and Rheumatism|December 1, 1996
Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative StudyD O Clegg, D J Reda, M H Weisman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 16, 2023
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory DiseasesMichelle W Cheung, Roya M Dayam, Janna R Shapiro, et al.
Annals of the Rheumatic Diseases|May 5, 2011
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisJ Braun, R van den Berg, X Baraliakos, et al.
Arthritis Care & Research|September 25, 2015
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisMichael M Ward, Atul Deodhar, Elie A Akl, et al.
Pageof 55